Search

Your search keyword '"Sumanasuriya, Semini"' showing total 178 results

Search Constraints

Start Over You searched for: Author "Sumanasuriya, Semini" Remove constraint Author: "Sumanasuriya, Semini"
178 results on '"Sumanasuriya, Semini"'

Search Results

1. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells

2. Applications of liquid biopsies in metastatic castration resistant prostate cancer

3. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA

4. CD38 in Advanced Prostate Cancers

5. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer

7. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

9. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer

10. Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers

11. BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer

13. Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital

14. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

15. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

16. Data from HER3 Is an Actionable Target in Advanced Prostate Cancer

17. Figure S1 from HER3 Is an Actionable Target in Advanced Prostate Cancer

18. Supplementary Data from HER3 Is an Actionable Target in Advanced Prostate Cancer

19. Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

20. Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

21. Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

22. Table S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

23. Supplementary Figure 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

24. Figure S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer

25. Supplementary Figure 3 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

26. Figure S5 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

27. Supplementary Table 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

28. Supplementary Figure 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

29. Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

30. Supplementary Legends from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer

31. Legends supplementary figures/ tables from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

32. Supplementary Methods from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

33. Data from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

34. Figure Legends from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

35. Supplementary Figures from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

36. Supplementary Tables from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

37. Abstract 3415: The neutrophil-to-lymphocyte ratio (NLR) reflects intratumor myeloid derived suppressor cell (MDSC) infiltration in metastatic castration-resistant prostate cancers (mCRPC)

39. HER3 Is an Actionable Target in Advanced Prostate Cancer

40. CD38 in Advanced Prostate Cancers

41. Abstract PO003: CD38 in the advanced prostate cancer

42. Abstract LB-270: Discovery of genomic correlates and tumor purity as an independent clinical factor of poor outcome in advanced prostate cancer lpWGS CNA data

43. Genomics of lethal prostate cancer at diagnosis and castration resistance

44. PSMA heterogeneity and DNA repair defects in prostate cancer.

45. Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.

46. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

47. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer

48. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency

49. Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

50. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

Catalog

Books, media, physical & digital resources